Annals of Nuclear Medicine最新文献

{"title":"Correlation between the thyroid computed tomography value and thyroid function in hyperthyroidism: a retrospective study","authors":"Haruna Iwanaga,&nbsp;Naotoshi Fujita,&nbsp;Shinji Abe,&nbsp;Shinji Naganawa,&nbsp;Katsuhiko Kato","doi":"10.1007/s12149-024-01938-0","DOIUrl":"10.1007/s12149-024-01938-0","url":null,"abstract":"<div><h3>Objective</h3><p>Radioiodine (I-131) therapy for hyperthyroidism is a well-established and safe treatment option. This study aimed to investigate the relationship between the computed tomography (CT) value and the function and volume of the thyroid gland by identifying the factors that induce changes in the CT value of patients with hyperthyroidism.</p><h3>Methods</h3><p>This retrospective study evaluated 38 patients with Graves’ disease and 10 patients with Plummer disease. To obtain the mean CT value and volume of the thyroid gland, the entire thyroid gland was set as the region of interest. A test dose of 3.7 MBq I-131 was administered before initiating I-131 therapy, and the radioiodine uptake (RIU) rate was assessed after 3, 24, 96, and 168 h. An approximate curve was plotted based on the RIU values obtained, and the effective half-life (EHL) was calculated. The correlation between the mean CT value and the volume of the thyroid gland, 24-h RIU, EHL, and the free triiodothyronine (FT3), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and TSH receptor antibody (TRAb) levels was evaluated.</p><h3>Results</h3><p>The CT value exhibited a significant positive correlation with EHL in patients with Graves’ disease (r = 0.62, <i>p</i> &lt; 0.0001) as well as patients with Plummer disease (r = 0.74, <i>p</i> &lt; 0.05). However, it did not display any correlation with the remaining parameters.</p><h3>Conclusion</h3><p>The CT value is significantly correlated with EHL, suggesting that it reflects thyroid function and is mainly related to the factors associated with iodine discharge.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 8","pages":"659 - 665"},"PeriodicalIF":2.5,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11282127/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141086402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual-time-point dynamic 68Ga-PSMA-11 PET/CT for parametric imaging generation in prostate cancer","authors":"Paphawarin Burasothikul,&nbsp;Chatchai Navikhacheevin,&nbsp;Panya Pasawang,&nbsp;Tanawat Sontrapornpol,&nbsp;Chanan Sukprakun,&nbsp;Kitiwat Khamwan","doi":"10.1007/s12149-024-01939-z","DOIUrl":"10.1007/s12149-024-01939-z","url":null,"abstract":"<div><h3>Purpose</h3><p>To investigate the optimal dual-time-point (DTP) approaches using dynamic ^<b>68</b>Ga-PSMA-11 PET/CT imaging to generate parametric images for prostate cancer patients.</p><h3>Methods</h3><p>Fifteen patients with prostate cancer were intravenously administered ⁶⁸Ga-PSMA-11 of 181.9 ± 47.2 MBq, followed by an immediate 60 min dynamic PET/CT scan. List-mode data were reconstructed into 25 timeframes (6 × 10 s, 8 × 30 s, and 11 × 300 s) and corrected for motion and partial volume effect. DTP parametric images were generated using different interval time points of 5 min and 10 min, with a minimum of 30 min time interval. Net influx rates (<i>K</i>_i) were calculated through the fitting of a single irreversible two-tissue compartmental model. Intraclass correlation coefficient (ICC) values between DTP protocols and 60 min <i>K</i>_i were obtained. Lesion-to-background ratios (LBRs) of <i>K</i>_i and standardized uptake value (SUV) images in each DTP protocol were determined.</p><h3>Results</h3><p>The DTP protocol of 5–10 min with a 40–45 min interval showed the highest ICC of 0.988 compared with the 60 min <i>K</i>_i, whereas the ICC values for the intervals of 0–5 min with 55–60 min and 0–10 min with 50–60 min were 0.941. The LBRs of the 60 min <i>K</i>_i, 5–10 min with 40–45 min <i>K</i>_i, 0–5 min with 55–60 min <i>K</i>_i, 0–10 min with 50–60 min <i>K</i>_i, SUV_mean, and SUV_max images were 29.53 ± 27.33, 13.05 ± 15.28, 45.15 ± 53.11, 45.52 ± 70.31, 19.77 ± 23.43, and 25.06 ± 30.07, respectively.</p><h3>Conclusion</h3><p>The 0–5 min with 55–60 min DTP parametric imaging exhibits a comparable <i>K</i>_i to 60 min parametric imaging and remarkable image quality and contrast than SUV imaging, enhancing prostate cancer diagnosis while maintaining time efficiency.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 9","pages":"700 - 710"},"PeriodicalIF":2.5,"publicationDate":"2024-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140955865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of hormone therapy on physiological uptake of the endometrium on [18F]F-FDG PET in postmenopausal women","authors":"Ryusuke Nakamoto,&nbsp;Masahiro Yakami,&nbsp;Tomomi W. Nobashi,&nbsp;Hiroyoshi Isoda,&nbsp;Yuji Nakamoto","doi":"10.1007/s12149-024-01941-5","DOIUrl":"10.1007/s12149-024-01941-5","url":null,"abstract":"<div><h3>Objective</h3><p>The effects of hormonal therapy, estrogen-based hormone replacement therapy (HRT), and anti-tumor hormone therapy, such as tamoxifen, on the physiological uptake of the endometrium on 2-deoxy-2[¹⁸F]fluoro-<span>d</span>-glucose ([¹⁸F]F-FDG) positron emission tomography (PET) in postmenopausal women have not been determined. We explored the effect of hormone therapy, particularly HRT, on physiological uptake in the endometrium of postmenopausal women.</p><h3>Materials and methods</h3><p>Postmenopausal women receiving hormone therapy who underwent cancer screening using PET/computed tomography (CT) between June 2016 and April 2023 were included in the hormone therapy group (<i>n</i> = 21). Postmenopausal women with no history of hormone therapy were included in the control group (<i>n</i> = 49). First, the physiological endometrial uptake at menopausal age and at least 1 year thereafter was compared quantitatively (SUVmax) and qualitatively (4-point scale) in the control group, to assess when the endometrium ceased to show significant physiological [¹⁸F]F-FDG uptake after menopause. Endometrial uptake was compared between the hormone therapy and control groups. The association between HRT duration (months) and endometrial uptake (SUVmax) was evaluated. Endometrial thickness, measured using transvaginal ultrasonography, was also compared between the two groups.</p><h3>Results</h3><p>Endometrial uptake was significantly reduced both qualitatively and quantitatively (<i>P</i> &lt; 0.05) at least 1 year after menopause in control patients, by which time most women (89.8%) no longer had significant endometrial uptake. The hormone therapy group (<i>n</i> = 21) showed higher FDG uptake in the endometrium compared to the control group (median SUVmax: 2.3 vs 1.9, <i>P</i> = 0.0011), as well as a higher visual score (<i>P</i> &lt; 0.0001). HRT duration did not correlate with endometrial uptake (<i>P</i> = 0.097). Endometrial thickness in the hormone therapy group was significantly thicker than in the control group (median: 3.9 mm vs 1.8 mm, <i>P</i> = 0.002).</p><h3>Conclusion</h3><p>Hormone therapy may affect physiological uptake in the endometrium in postmenopausal women.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 9","pages":"726 - 733"},"PeriodicalIF":2.5,"publicationDate":"2024-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140955801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of 68Ga-PSMA-11 PET/CT: a Phase 1 clinical study in Japanese patients with primary, recurrent, or suspected recurrent prostate cancer","authors":"Anri Inaki,&nbsp;Atsushi Mizokami,&nbsp;Hiroshi Wakabayashi,&nbsp;Kouji Izumi,&nbsp;Yoshifumi Kadono,&nbsp;Tadashi Toyama,&nbsp;Shizuko Takahara,&nbsp;Toshinori Murayama,&nbsp;Seigo Kinuya","doi":"10.1007/s12149-024-01931-7","DOIUrl":"10.1007/s12149-024-01931-7","url":null,"abstract":"<div><h3>Background</h3><p>Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals allow whole-body imaging to detect prostate cancer (PC). Positron emission tomography imaging using gallium-68 (⁶⁸Ga)-PSMA-11 has been shown to have a favorable safety and tolerability profile and high diagnostic performance. The study evaluates the safety and pharmacokinetics of ⁶⁸Ga-PSMA-11 in Japanese patients with primary, recurrent, or suspected recurrent prostate cancer.</p><h3>Methods</h3><p>This single arm study enrolled Japanese patients with primary PC (<i>n</i> = 3), suspected recurrent PC following radical prostatectomy (<i>n</i> = 4), or suspected recurrent PC following radical radiotherapy (<i>n</i> = 3). All patients received a single intravenous dose of ⁶⁸Ga-PSMA-11 2.0 MBq/kg (±10%) followed by PSMA PET imaging and safety and pharmacokinetic evaluations. Based on the blood concentrations of ⁶⁸Ga-PSMA-11 and the radioactivity distribution rate in each organ/tissue, the absorbed doses in major organs/tissues and the whole-body effective dose were calculated by the Medical Internal Radiation Dose method.</p><h3>Results</h3><p>Ten patients were enrolled. Mean age was 73.3 ± 4.8 years, and median prostate-specific antigen was 8.250 ng/mL. Five patients (50%) experienced a total of 6 adverse events, and no grade ≥ 2 adverse events or serious adverse events were reported. No clinically significant changes in vital signs, haematology parameters, or blood chemistry or ECG abnormalities were observed. The estimated whole body effective dose of ⁶⁸Ga-PSMA-11 (mean ± standard deviation) was 2.524 × 10^–2 ± 2.546 × 10^–3 mSv/MBq. Time to maximum concentration (1.16 × 10^–4 ± 1.3 × 10^–5% ID/mL) in whole blood was 2.15 ± 0.33 min.</p><h3>Conclusions</h3><p>⁶⁸Ga-PSMA-11 has a favourable safety and tolerability profile in Japanese patients with primary, recurrent, or suspected recurrent prostate cancer, which is comparable to previous observations in other populations.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 8","pages":"587 - 595"},"PeriodicalIF":2.5,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11281955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140943882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance of F-18 FDG PET/CT in differentiating autoimmune pancreatitis from pancreatic cancer: a systemic review and meta-analysis","authors":"Deepanksha Datta,&nbsp;B. Selvakumar,&nbsp;Akhil Dhanesh Goel,&nbsp;Sanskriti Chhibber,&nbsp;Vaibhav Kumar Varshney,&nbsp;Rajesh Kumar","doi":"10.1007/s12149-024-01934-4","DOIUrl":"10.1007/s12149-024-01934-4","url":null,"abstract":"<div><h3>Objectives</h3><p>This study aims to evaluate the utility of F-18 FDG PET/CT in the non-invasive diagnosis of autoimmune pancreatitis (AIP) and differentiating it from pancreatic cancer (CaP) based on the amount and pattern of FDG uptake, as well as involvement of extra-pancreatic sites.</p><h3>Methods</h3><p>A systematic search was conducted using PubMed, Scopus, Cochrane Library and Google Scholar. Only those studies that compared the findings of F-18 FDG PET/CT in terms of SUVmax, pattern of FDG uptake and presence of FDG-avid extra-pancreatic sites in both AIP and CaP were included. Studies were qualitatively assessed for risk of bias and publication bias. The diagnostic performance of parameters on PET/CT was examined through pooled sensitivity, specificity, diagnostic odd’s ratio (DOR) and summary receiver operator characteristic (SROC) curve analysis.</p><h3>Results</h3><p>Six studies were included with a total of 580 patients. 178 patients had AIP (Age 18–90 years, male, M: female, F ratio—8.4:1) and 402 patients had CaP (Age 22–88 years, M:F ratio-1.5:1). Type of AIP was reported in only 3 studies, with the included cases predominantly being type 1 AIP. All studies were retrospective with heterogeneity and a risk on patient selection and index test. The FDG uptake, expressed as SUVmax, was lower in AIP with a weighted mean difference of −3.11 (95% confidence interval, CI: −5.28 to −0.94). To diagnose AIP, the pooled sensitivity, specificity and DOR of diffuse pattern of FDG uptake were 0.59 (95% CI: 0.51–0.66), 0.89 (95% CI: 0.86–0.92) and 21.07 (95% CI: 5.07–88.32), respectively, with an area under curve (AUC) of 0.717 on SROC analysis. The pooled sensitivity, specificity and DOR of FDG-avid extra pancreatic sites were 0.55 (95% CI: 0.45–0.65), 0.58 (95% CI: 0.52–0.64) and 2.33 (95% CI: 1.40–3.89), respectively, with an AUC of 0.632.</p><h3>Conclusion</h3><p>On F-18 FDG PET/CT, a pancreatic lesion of AIP has a lower SUVmax value than CaP. A diffuse pattern of FDG uptake and presence of an extra-pancreatic FDG-avid site are nearly 21 times and twice more likely in AIP than CaP, respectively.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 8","pages":"619 - 629"},"PeriodicalIF":2.5,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140943880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic value of lymph node to primary tumor standardized uptake value ratio in cancer patients: a meta-analysis","authors":"Wing-Keen Yap,&nbsp;Ken-Hao Hsu,&nbsp;Ting-Hao Wang,&nbsp;Chia-Hsin Lin,&nbsp;Chung-Jan Kang,&nbsp;Shih-Ming Huang,&nbsp;Huan-Chun Lin,&nbsp;Tsung-Min Hung,&nbsp;Kai-Ping Chang,&nbsp;Tsung-You Tsai","doi":"10.1007/s12149-024-01933-5","DOIUrl":"10.1007/s12149-024-01933-5","url":null,"abstract":"<div><h3>Objective</h3><p>The lymph node to primary tumor standardized uptake value ratio (NTR) is an innovative parameter derived from positron emission tomography/computed tomography (PET/CT) scans that captures the intricate relationship between primary tumors and associated lymph nodes. This meta-analysis aimed to investigate the prognostic value of NTR in cancer patients.</p><h3>Methods</h3><p>A systematic search of PubMed, Cochrane, and Embase databases was conducted to identify studies investigating the association between NTR and survival outcomes in cancer patients. The pooled adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) were calculated using a random-effects model.</p><h3>Results</h3><p>Twelve studies comprising a total of 2037 patients were included in the meta-analysis. Elevated NTR was significantly associated with worse overall survival aHR (2.21, 95% CI 1.63 to 2.99), disease-free survival aHR (3.27, 95% CI 2.12 to 5.05), and distant metastasis-free survival aHR (2.07, 95% CI 1.55 to 2.78) in cancer patients. Subgroup analyses by cancer type showed consistent results across various malignancies, including head and neck squamous cell carcinoma, endometrial carcinoma, lung cancer, breast cancer, and nasopharyngeal carcinoma.</p><h3>Conclusions</h3><p>This meta-analysis provides evidence for a significant association between elevated NTR and worse survival outcomes in cancer patients. Elevated NTR may serve as a useful prognostic biomarker for cancer patients and could potentially be used to guide treatment decisions and monitor disease progression. Future studies should aim to validate these findings in larger and more diverse patient populations and investigate the underlying mechanisms for the observed association between NTR and survival outcomes.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 8","pages":"607 - 618"},"PeriodicalIF":2.5,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140896890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"11C-Methionine uptake in meningiomas after stereotactic radiotherapy","authors":"Hanne-Rinck Jeltema,&nbsp;Bart R. J. van Dijken,&nbsp;Katalin Tamási,&nbsp;Gea Drost,&nbsp;Mart A. A. M. Heesters,&nbsp;Anouk van der Hoorn,&nbsp;Andor W. J. M. Glaudemans,&nbsp;J. Marc C. van Dijk","doi":"10.1007/s12149-024-01932-6","DOIUrl":"10.1007/s12149-024-01932-6","url":null,"abstract":"<div><h3>Objective</h3><p>¹¹C-Methionine positron emission tomography (MET-PET) is used for stereotactic radiotherapy planning in meningioma patients. The role of MET-PET during subsequent follow-up (FU) is unclear. We analyzed the uptake of ¹¹C-Methionine before and after stereotactic radiotherapy (SRT) in patients with a complex meningioma and investigated if there was a difference between patients with progressive disease (PD) and stable disease (SD) during FU.</p><h3>Methods</h3><p>This retrospective study investigates 62 MET-PETs in 29 complex meningioma patients. Standardized uptake value (SUV)_max and SUV_peak tumor-to-normal ratios (T/N-ratios) were calculated, comparing the tumor region with both the mirroring intracranial area and the right frontal gray matter. The difference in ¹¹C-Methionine uptake pre- and post-SRT was analyzed, as well as the change in uptake between PD or SD.</p><h3>Results</h3><p>Median (IQR) FU duration was 67 months (50.5–91.0). The uptake of ¹¹C-Methionine in meningiomas remained increased after SRT. Neither a statistically significant difference between MET-PETs before and after SRT was encountered, nor a significant difference in one of the four T/N-ratios between patients with SD versus PD with median (IQR) SUV_max T/N_{R front} 2.65 (2.13–3.68) vs 2.97 (1.55–3.54) [<i>p</i> = 0.66]; SUV_max T/N_mirror 2.92 (2.19–3.71) vs 2.95 (1.74–3.60) [<i>p</i> = 0.61]; SUV_peak T/N_{R front} 2.35 (1.64–3.40) vs 2.25 (1.44–3.74) [<i>p</i> = 0.80]; SUV_peak T/N_mirror 2.38 (1.91–3.36) vs 2.35 (1.56–3.72) [<i>p</i> = 0.95].</p><h3>Conclusions</h3><p>Our data do not support use of MET-PET during FU of complex intracranial meningiomas after SRT. MET-PET could not differentiate between progressive or stable disease.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 8","pages":"596 - 606"},"PeriodicalIF":2.5,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11282149/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140890814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Animal PET scanner with a large field of view is suitable for high-throughput scanning of rodents","authors":"Yuki Tomonari,&nbsp;Yuya Onishi,&nbsp;Fumio Hashimoto,&nbsp;Kibo Ote,&nbsp;Takashi Okamoto,&nbsp;Hiroyuki Ohba","doi":"10.1007/s12149-024-01937-1","DOIUrl":"10.1007/s12149-024-01937-1","url":null,"abstract":"<div><h3>Objective</h3><p>In preclinical studies, high-throughput positron emission tomography (PET) imaging, known as simultaneous multiple animal scanning, can reduce the time spent on animal experiments, the cost of PET tracers, and the risk of synthesis of PET tracers. It is well known that the image quality acquired by high-throughput imaging depends on the PET system. Herein, we investigated the influence of large field of view (FOV) PET scanner on high-throughput imaging.</p><h3>Methods</h3><p>We investigated the influence of scanning four objects using a small animal PET scanner with a large FOV. We compared the image quality acquired by four objects scanned with the one acquired by one object scanned using phantoms and animals. We assessed the image quality with uniformity, recovery coefficient (RC), and spillover ratio (SOR), which are indicators of image noise, spatial resolution, and quantitative precision, respectively. For the phantom study, we used the NEMA NU 4-2008 image quality phantom and evaluated uniformity, RC, and SOR, and for the animal study, we used Wistar rats and evaluated the spillover in the heart and kidney.</p><h3>Results</h3><p>In the phantom study, four phantoms had little effect on imaging quality, especially SOR compared with that for one phantom. In the animal study as well, four rats had little effect on spillover from the heart muscle and kidney cortex compared with that for one rat.</p><h3>Conclusions</h3><p>This study demonstrated that an animal PET scanner with a large FOV was suitable for high-throughput imaging. Thus, the large FOV PET scanner can support drug discovery and bridging research through rapid pharmacological and pathological evaluation.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 7","pages":"544 - 552"},"PeriodicalIF":2.5,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140875658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of combining clinical factors, 18F-FDG PET-based intensity, volumetric features, and deep learning predictor in patients with EGFR-mutated lung adenocarcinoma undergoing targeted therapies: a cross-scanner and temporal validation study","authors":"Kun-Han Lue,&nbsp;Yu-Hung Chen,&nbsp;Sung-Chao Chu,&nbsp;Chih-Bin Lin,&nbsp;Tso-Fu Wang,&nbsp;Shu-Hsin Liu","doi":"10.1007/s12149-024-01936-2","DOIUrl":"10.1007/s12149-024-01936-2","url":null,"abstract":"<div><h3>Objective</h3><p>To investigate the prognostic value of ¹⁸F-FDG PET-based intensity, volumetric features, and deep learning (DL) across different generations of PET scanners in patients with epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma receiving tyrosine kinase inhibitor (TKI) treatment.</p><h3>Methods</h3><p>We retrospectively analyzed the pre-treatment ¹⁸F-FDG PET of 217 patients with advanced-stage lung adenocarcinoma and actionable EGFR mutations who received TKI as first-line treatment. Patients were separated into analog (<i>n</i> = 166) and digital (<i>n</i> = 51) PET cohorts. ¹⁸F-FDG PET-derived intensity, volumetric features, ResNet-50 DL of the primary tumor, and clinical variables were used to predict progression-free survival (PFS). Independent prognosticators were used to develop prediction model. Model was developed and validated in the analog and digital PET cohorts, respectively.</p><h3>Results</h3><p>In the analog PET cohort, female sex, stage IVB status, exon 19 deletion, SUV_max, metabolic tumor volume, and positive DL prediction independently predicted PFS. The model devised from these six prognosticators significantly predicted PFS in the analog (HR = 1.319, <i>p</i> &lt; 0.001) and digital PET cohorts (HR = 1.284, <i>p</i> = 0.001). Our model provided incremental prognostic value to staging status (c-indices = 0.738 vs. 0.558 and 0.662 vs. 0.598 in the analog and digital PET cohorts, respectively). Our model also demonstrated a significant prognostic value for overall survival (HR = 1.198, <i>p</i> &lt; 0.001, c-index = 0.708 and HR = 1.256, <i>p</i> = 0.021, c-index = 0.664 in the analog and digital PET cohorts, respectively).</p><h3>Conclusions</h3><p>Combining ¹⁸F-FDG PET-based intensity, volumetric features, and DL with clinical variables may improve the survival stratification in patients with advanced EGFR-mutated lung adenocarcinoma receiving TKI treatment. Implementing the prediction model across different generations of PET scanners may be feasible and facilitate tailored therapeutic strategies for these patients.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 8","pages":"647 - 658"},"PeriodicalIF":2.5,"publicationDate":"2024-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140858690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of 68 Ga-FAPI PET/CT in patients with bone metastases in various cancers","authors":"Hacı Arak,&nbsp;Umut Elboga,&nbsp;Yusuf Burak Cayirli,&nbsp;Aydın Aytekin","doi":"10.1007/s12149-024-01935-3","DOIUrl":"10.1007/s12149-024-01935-3","url":null,"abstract":"<div><h3>Objective</h3><p>This study aimed to compare ¹⁸FDGPET/CT in patients who develop bone metastases due to various cancers and to investigate the prognostic significance of the ⁶⁸FAPI-PET/CT SUVmax value for survival.</p><h3>Methods</h3><p>Patients with bone metastases who underwent both ⁶⁸ Ga-FAPI PET/CT and ¹⁸FDGPET/CT within a 1 week period were included in this retrospective study. The effect of the SUVmax value of bone lesions on overall survival was analyzed.</p><h3>Results</h3><p>A total of 75 eligible patients with 139 bone lesions were included in this study. The median age of the patients was 55 (30–83) and 48(64%) patients were newly diagnosed. The primary lesion median ⁶⁸ Ga-FAPI PET/CT SUVmax value was higher than the median ¹⁸FDGPET/CT SUVmax (10.75 versus 6.7). Bone lesions ⁶⁸ Ga-FAPI PET/CT SUVmax median (IQR) were 7.8 (4.6–13.2), and ¹⁸FDGPET/CT SUVmax of bone lesions were 5.9 (3.8–8.2). More bone lesions were detected on ⁶⁸ Ga-FAPI PET/CT than on ¹⁸FDGPET/CT(median IQR 4 [1–9] versus 2 [1–6] (<i>p</i> = 0.014). The extra lesions observed on ⁶⁸ Ga-FAPI PET/CT were mostly sclerotic bone lesions (<i>p</i> = 0.001).⁶⁸ Ga-FAPI PET/CT SUVmax was significantly higher in vertebra and thorax lesions (<i>p</i> = 0.011 and <i>p</i> = 0.018, respectively). While the bone lesion ⁶⁸ Ga-FAPI PET/CT SUVmax affected the OS, the ¹⁸FDGPET/CT SUVmax value did not affect the OS (<i>p</i> &lt; 0.001 and <i>p</i> = 0.079, respectively). In ROC analysis, a cut-off-off value of ⁶⁸ Ga-FAPI PET/CT SUVmax &gt; 7.7 was found for OS (AUC: 0.619). The median OS in the group above the cut-off value was worse than that in the group below the cut-off value (32 versus 45) months (<i>p</i> = 0.002). In the multivariate analysis for OS, the ⁶⁸ Ga-FAPI PET/CT SUVmax of bone lesions was an important parameter, as well as cancer subtype, ALP level, and disease occurrence.</p><h3>Conclusions</h3><p>⁶⁸ Ga-FAPI PET/CT detected more bone lesions and higher SUVmax values than ¹⁸FDGPET/CT in various cancers. The prognostic value of the SUVmax value of ⁶⁸ Ga-FAPI PET/CT bone lesions was observed regardless of disease subtype.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 8","pages":"630 - 638"},"PeriodicalIF":2.5,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140837504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}